NCT05183347View on ClinicalTrials.gov

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 4, 2022

Primary Completion Date

July 27, 2022

Study Completion Date

July 27, 2022

Conditions
Healthy
Interventions
DRUG

BI 1291583

BI 1291583

DRUG

Placebo

Placebo

Trial Locations (1)

130-0004

SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05183347 - A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated | Biotech Hunter | Biotech Hunter